Overview / Research screener / Niacin
OTC Nutraceuticals
Niacin (vitamin B3, NAD+ precursor)
nad mitochondrial
Sold as a consumer product in 1 of 9 markets tracked; in clinical trials in 1.
1 randomized trial (47 people, 12 months). It improved its main endpoint, a measure of physical or cognitive function.
Doses studied: 250 mg.
Evidence map
main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported
Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.
What each study measured
Harms reported
Where it is available
If you are tracking this yourself
Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.
What would change this picture
Trials under way
Every study (4)
- T7 Chong 2021 Niacin Enhancement for Parkinson’s Disease: An Effectiveness Trial doi:10.3389/fnagi.2021.667032
- T5 Xiang 2025 Association of dietary niacin intake with all-cause mortality in chronic kidney disease patients: A retrospective cohort study doi:10.1371/journal.pone.0313398
- T5 Ying 2022 Dietary niacin intake and mortality among cancer patients: NHANES 1999-2014 doi:10.1186/s12885-022-10265-4
- TX Keenan 2024 The Niacin Rebirth: Revisiting the Potential of Nicotinic Acid Therapy for Cardiovascular Disease and Niacin Supplementation for Healthy Aging doi:10.18103/mra.v12i7.5521